CALM1: Calmodulin-1
Calmodulin acts as part of a calcium signal transduction pathway by mediating the control of a large number of enzymes, ion channels, aquaporins and other proteins through calcium-binding.
- Drugs that act on it: 2
- Approved: 2
- In phases 1 to 3: 0
- Sponsors: 0
Who is on it, and how far along
Every drug ChEMBL records acting on CALM1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
| BenziodaroneWithdrawn | Approved | — | Small molecule | InhibitorCalmodulin inhibitor | 0 |
| PrenylamineWithdrawn | Approved | — | Small molecule | InhibitorCalmodulin inhibitor | 0 |
- Long QT syndrome 140.78
- Catecholaminergic polymorphic ventricular tachycardia 40.75
- Catecholaminergic polymorphic ventricular tachycardia0.57
- Cardiovascular disorder0.53
- Bacterial infectious disease0.50
- Prolonged QT interval0.49
- Abnormality of the cardiovascular system0.44
- Familial long QT syndrome0.41
- Anthrax infection0.37
- Catecholaminergic polymorphic ventricular tachycardia 10.27
- Placental abruption0.10
- Cancer0.10
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL6093, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P0DP23, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets